A high-throughput liquid bead array assay confirms strong correlation between SARS-CoV-2 antibody level and COVID-19 severity

iScience

Eric Brady¹  Gordon R. Bernard²  Jillian P. Rhoads²  Sandra Yoder²  Isaac Thomsen³  C. Buddy Creech⁴  Allison P. Wheeler⁴  Monique Bennett⁵  Jill M. Pulley⁵  Thomas G. Stewart⁵ 

[1] Vanderbilt Institute for Infection, Immunology and Inflammation (VI4), Vanderbilt University Medical Center, Nashville, TN, USA;Vanderbilt Vaccine Research Program, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA;Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA;

关键词: Biological Sciences;    Microbiology;    Virology;    Viral Microbiology;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: A detailed understanding of the adaptive host response to SARS-CoV-2 infection in humans is urgently needed. We developed a sensitive, high-throughput, and efficient assay using liquid bead array technology. We observed advantages over traditional ELISA for the detection and quantification of binding IgG against the receptor binding domain (RBD) of SARS-CoV-2. To determine whether COVID-19 symptom severity correlates with SARS-CoV-2 IgG, we measured anti-RBD IgG levels from 67 subjects recovered from PCR-confirmed COVID-19. We found that COVID-19 symptom severity strongly correlated with RBD IgG level (p < 0.001). These findings have substantial implications for public policy surrounding assessments of antibody responses and possible immunity, as not all cases of COVID-19 can be assumed to generate a protective antibody response, and mild disease in particular is capable of generating very low-level anti-RBD IgG levels. These findings also have important implications for the selection of donors for convalescent plasma to be used therapeutically.

【 授权许可】

Unknown